MAESTRO - Robotique chirurgicale nouvelle génération.
Seance of wednesday 11 march 2026 (Chirurgie 4.0 : IA et technologies intelligentes Surgery 4.0: AI & Smart Technologies)
DOI number : 10.26299/vz23-te84/2026.11.03
Abstract
Maestro is introducing a new category of equipment: surgical cobotics, or collaborative robotics, which complements teleoperation robots.
But above all, it is an AI-enhanced robotic assistance platform designed for high-volume, intermediate-complex surgery. The Maestro Insights® module consolidates procedure, room, and consumables data, and continuous analysis of this data improves surgical quality by capitalizing on previous cases and the experience of international peers.
Access to robotics is becoming financially and organizationally accessible to public and private institutions that were previously excluded. The impact of Maestro, which is compatible with standard instruments, can be measured cumulatively: clinical gains through a reduction of approximately 10% in operating time, operational gains through a reduction of approximately 25% in operating variability, HR gains with the possibility of freeing up a surgical nurse, and capacity gains as the fluidity allows one additional patient per day and per session.
The platform's objectives, with the surgeon bedside, are efficiency, autonomy, and appropriate technological care: reserving remote manipulation for complex cases and entrusting Maestro with standard cases for optimal allocation of public and private resources.
Maestro's AI architecture is based on edge computing, unlike cloud-based models, and therefore does not compromise on security or data sovereignty.
This trajectory validates the model: a disruptive French technology, approved by regulators in Europe and the United States, with more than 2,500 patients worldwide having undergone surgery with the help of Maestro to date.
But above all, it is an AI-enhanced robotic assistance platform designed for high-volume, intermediate-complex surgery. The Maestro Insights® module consolidates procedure, room, and consumables data, and continuous analysis of this data improves surgical quality by capitalizing on previous cases and the experience of international peers.
Access to robotics is becoming financially and organizationally accessible to public and private institutions that were previously excluded. The impact of Maestro, which is compatible with standard instruments, can be measured cumulatively: clinical gains through a reduction of approximately 10% in operating time, operational gains through a reduction of approximately 25% in operating variability, HR gains with the possibility of freeing up a surgical nurse, and capacity gains as the fluidity allows one additional patient per day and per session.
The platform's objectives, with the surgeon bedside, are efficiency, autonomy, and appropriate technological care: reserving remote manipulation for complex cases and entrusting Maestro with standard cases for optimal allocation of public and private resources.
Maestro's AI architecture is based on edge computing, unlike cloud-based models, and therefore does not compromise on security or data sovereignty.
This trajectory validates the model: a disruptive French technology, approved by regulators in Europe and the United States, with more than 2,500 patients worldwide having undergone surgery with the help of Maestro to date.